C.M. Bidwell & Associates’s Kindred Biosciences, Inc. KIN Stock Holding History

C.M. Bidwell & Associates’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-9,145	Closed	-$79K	–	470
2018 Q1	$79K	Sell	9,145 -16,165	-64%	-$142K	0.07%	214
2017 Q4	$239K	Sell	25,310 -10,425	-29%	-$81.4K	0.21%	133
2017 Q3	$281K	Buy	+35,735	New	+$268K	0.43%	91

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

PVAM

Pacific View Asset Management San Francisco, California $20.8M AUM 20.08% 1-Year Est. Return

C.M. Bidwell & Associates's KIN Position: Q2 2018 in Review

C.M. Bidwell & Associates sold out of Kindred Biosciences, Inc. (KIN) in Q2 2018, closing a stake of 9,145 shares — an estimated $79K sold.

C.M. Bidwell & Associates first reported a position in KIN in Q3 2017 and held it in 3 quarters. The position peaked at $281K in Q3 2017. 73 funds tracked by Wall St. Rank hold KIN as of Q2 2018.

C.M. Bidwell & Associates reported no remaining Kindred Biosciences, Inc. position as of Q2 2018 after selling out during the quarter.
C.M. Bidwell & Associates sold 9,145 Kindred Biosciences, Inc. shares in Q2 2018, an estimated $79K.
C.M. Bidwell & Associates first reported a position in Kindred Biosciences, Inc. in Q3 2017 and held it in 3 quarters.
C.M. Bidwell & Associates's Kindred Biosciences, Inc. position peaked at $281K in Q3 2017.
73 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2018, filed 13 Aug 2018.